The International Journal of Frontier Sciences

(ISSN: 2618-0367) Open Access Journal
Rss Feed:
image missing

Table of Contents

Int J Front Sci, Volume 8, Issue 2 (July 2026)
select all articles
Export citation of selected articles as:
1 Department of Biotechnology, International Institute of Science, Arts and Technology (IISAT), Gujranwala 52250, Pakistan
* Author to whom correspondence should be addressed.
Int J Front Sci 2026, 8(2), 7; doi: 10.37978/tijfs.v08i02.007
Received: 20 Aug 2026 / Accepted: 21 Oct 2026 / Published: 13 Nov 2026
Background: As the world witnesses remarkable advances in targeted drug and gene delivery, we see the emergence of two important nanocarrier-based systems for accurate destination locking, lipid nanoparticles (LNPs) and polymersomes, with the promise of providing precision, efficiency and accuracy in therapeutic drug load transport. With sufficient tunability, impressive physicochemical properties and the potential for controlled release, both these systems appear to be a great solution to problems like biodistribution and lability. Despite the advanced research and their clinical utility, challenges remain in achieving site-specific targeting, large-scale reproducibility, and long-term safety. Methods: A detailed literature review was conducted to study the detailed differences in mechanism, types and effectivity of various polymeric and lipid-based nanoparticles for targeted drug delivery by reviewing the published peer-reviewed articles from recent years. Results: This review combines current developments in engineering strategies for functionalization, stimuli responsiveness, and hybrid design of LNPs and polymersomes while comparing the advantages, hurdles and regulatory considerations. Finally, emerging directions in precision nanomedicine such as bioinspired nanocarriers, AI-assisted formulation design, and multifunctional theranostic systems are discussed as pathways toward more effective, targeted and personalized therapies. Conclusions: The literature study suggests that only LNPs have been approved for clinical applications whereas polymersomes are in a translational pipeline. However, both LNPs and polymeric nanoparticles have their own significance and uses in biological applications, in enhancing biocompatibility and bioavailability of both hydrophobic and hydrophilic drugs. Full article